Aastrom Biosciences CEO to Present at Rodman & Renshaw Techvest 7th Annual Healthcare Conference
04 November 2005 - 7:58AM
PR Newswire (US)
ANN ARBOR, Mich., Nov. 3 /PRNewswire-FirstCall/ -- Aastrom
Biosciences, Inc. (NASDAQ:ASTM) announced today R. Douglas
Armstrong, Ph.D., Chairman and Chief Executive Officer, will
present at the Rodman & Renshaw Techvest 7th Annual Healthcare
Conference. The conference will be held November 7-9, 2005 at the
New York Palace Hotel in New York, NY. Dr. Armstrong will present
at 10:10 a.m. (ET) on Monday, November 7th. Rodman & Renshaw,
LLC is a privately-held, full-service investment bank committed to
fostering the long-term success of emerging growth companies
through capital raising, strategic advice, insightful research, and
the development of institutional support. A live webcast of
Aastrom's presentation can be accessed by logging onto the web at
http://wsw.com/webcast/rrshq7/astm/. An archived replay of the
presentation will also be available after the conference for 90
days, at the same site. For more information about the Rodman &
Renshaw Techvest 7th Annual Healthcare Conference, please visit
Rodman & Renshaw's website at http://www.rodmanandrenshaw.com/.
About Aastrom Biosciences, Inc. Aastrom Biosciences, Inc.
(NASDAQ:ASTM) is developing patient-specific products for the
repair or regeneration of human tissues, utilizing the Company's
proprietary adult stem cell technology. Aastrom's strategic
position in the tissue regeneration sector is enabled by its
proprietary Tissue Repair Cells (TRCs), a mix of bone
marrow-derived adult stem and progenitor cells manufactured in the
AastromReplicell(R) System, an industry- unique automated cell
production system. TRCs are the core component of the products
Aastrom is developing for severe bone fractures, ischemic vascular
disease, jaw reconstruction and spine fusion, with Phase I/II level
clinical trials active in the U.S. and EU for some of these
indications. For more information, visit Aastrom's website at
http://www.aastrom.com/. This document contains forward-looking
statements, including without limitation, statements concerning
planned clinical trials, product development objectives, potential
advantages of TRCs, and potential product applications, which
involve certain risks and uncertainties. The forward-looking
statements are also identified through use of the words "planned,"
and other words of similar meaning. Actual results may differ
significantly from the expectations contained in the
forward-looking statements. Among the factors that may result in
differences are potential patient accrual difficulties, clinical
trial results, potential product development difficulties, the
effects of competitive therapies, regulatory approval requirements,
the availability of financial and other resources and the
allocation of resources among different potential uses. These and
other significant factors are discussed in greater detail in
Aastrom's Annual Report on Form 10-K and other filings with the
Securities and Exchange Commission. CONTACTS: Kris M. Maly or
Cameron Associates Becky Anderson Kevin McGrath - Institutions
Investor Relations Department Phone: (212) 245-4577 Aastrom
Biosciences, Inc. Alyson Nikulicz - Media Phone: (734) 930-5777
Phone: (212) 554-5464 DATASOURCE: Aastrom Biosciences, Inc.
CONTACT: Kris M. Maly or Becky Anderson both of Investor Relations
Department, Aastrom Biosciences, Inc., +1-734-930-5777; or Kevin
McGrath - Institutions, +1-212-245-4577, or Alyson Nikulicz -
Media, +1-212-554-5464 both of Cameron Associates Web site:
http://www.aastrom.com/
Copyright
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From Jun 2024 to Jul 2024
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From Jul 2023 to Jul 2024